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Hepatic encephalopathy (HE) represents a spectrum of neurocognitive impairment in cirrhosis (SONIC) \[[@CR1]\]. It constitutes of two major components: overt HE (OHE) and minimal HE (MHE) \[[@CR2]\]. OHE can be diagnosed clinically, whereas MHE requires specialized testing. It has been estimated that OHE is present in 30--45% of patients with cirrhosis \[[@CR3]\], compared with approximately 60--80% of patients who have evidence of MHE \[[@CR4]\]. MHE can potentially progress to OHE and is associated with high mortality, poor quality of life, and a high risk of motor vehicle accidents \[[@CR5]\]. HE continues to pose a major healthcare burden on patients, caregivers, and society \[[@CR6]•\]. It has been reported that the healthcare costs for patients with HE are likely to increase over the coming years \[[@CR7]\]. There are several clinical systems to diagnose the severity of HE \[[@CR8]--[@CR10]\]. However, most of them are subjective and not reproducible because of lack of objective criteria for the clinical diagnosis of HE \[[@CR11]\]. The West-Haven criteria are the most widely used; however, they also lack objectivity through the entire spectrum of HE \[[@CR12]\]. Other tests that can assist with diagnosing HE are clinical hepatic encephalopathy staging scale (CHESS) \[[@CR13]\] and the Hepatic Encephalopathy Scoring Algorithm (HESA) \[[@CR11]\] \[[@CR14]\]. When making a clinical diagnosis of HE, it is important to exclude other etiologies that can lead to alteration in mental status, and to specifically investigate the cognitive function as well. Deterioration in mental status and in psychometric or neurophysiological function are the two levels of cognitive function that need to be acknowledged given the fact that clinical exam can diagnose mental status changes only.

Factors That Impair Cognitive Function {#Sec2}
======================================

There are many factors that can precipitate HE in cirrhosis patients, which include infections, GI bleeding, electrolyte disorder, constipation, and diuretic overdose. Patients with alcohol-related cirrhosis exhibit more severe neurocognitive changes and more cortical lesions post-transjugular intrahepatic portosystemic shunt (TIPS) placement based on brain MRI compared with individuals with cirrhosis from other etiologies \[[@CR15]••\]. Recent data suggest that patients with non-alcoholic steatohepatitis (NASH) are at risk for premature brain aging due to the presence of early cerebral atrophy \[[@CR16]\]. Large studies have shown an association between hepatitis C virus (HCV) infection and increased risk of neurodegenerative disorders \[[@CR17]\]. Global brain reserve is a term that describes a combination of structural changes (brain reserve) and the individual's ability to endure alterations (cognitive reserve) \[[@CR18]\]. Changes in global reserve have been shown to impact the progression of brain diseases such as dementia and multiple sclerosis \[[@CR19], [@CR20]\]. Cognitive reserve reflects the dynamic neuroadaptation that derives from socio-economic and educational factors. It has been shown to modulate the impact of brain disease or neurocognitive insults such as HE \[[@CR21]••\]. In contrast to cognitive reserve, brain reserve is less adaptable and is dependent on disease etiology, severity, and progression \[[@CR19]\]. The capacity of brain reserve was reported to be implicated in the lack of direct correlation between the clinical manifestations of brain diseases and the objective findings obtained by imaging or neurophysiological tests \[[@CR22]\]. Variables such as education level \[[@CR23]\], psychometrical intelligence \[[@CR24]\], leisure time activities \[[@CR25]\], and lifestyle \[[@CR26]\] determine the brain's ability to cope with damage. The expression of HE phenotype is determined by two opposing forces: cognitive reserve (resilience factor) and neuropsychiatric comorbidity (precipitating factor). It has been reported that patients with cirrhosis and higher cognitive reserve, regardless of degree of liver failure, have better quality of life \[[@CR21]••, [@CR27]\]. The Barona Index is a validated IQ analysis which consists of age, sex, race, education, occupation, residence type (urban or rural), and region of residence (locations within the USA) \[[@CR28]\]. It is an optimal method for testing pre-morbid intelligence that follows subject cognitive performance \[[@CR29]\]. The Barona IQ is divided into the verbal IQ (VIQ), performance IQ (PIQ), and the full scale IQ (FSIQ). High cognitive reserve is defined as FSIQ ≥ 109 while lower than 109 is considered average cognitive reserve \[[@CR30]\]. Cognitive Reserve Index questionnaire (CRIq) is another tool that produces CRI which reflects the amount of cognitive reserve based on educational level, work activities, and frequency of leisure time activities \[[@CR31]\]. CRIq is different from the Barona Index because it measures long-life activities that modulate cognitive skills, and can be complimentary to the Barona Index in correlating between IQ and health-related quality of life in patients with cirrhosis \[[@CR21]••\].

Changes in Brain Function After Transplant {#Sec3}
==========================================

Liver transplantation (LT) remains the gold standard treatment for HE refractory to other treatments, but it carries risks. It has been shown that manifestations of HE are not completely fully reversible by transplantation as it may induce impairment of brain function \[[@CR32]\]. The development of postoperative confusional syndrome is a problem of considerable magnitude due to the difficulty in finding the underlying etiology of alteration in mental status, and the likelihood of presence of multiple causes (Fig. [1](#Fig1){ref-type="fig"}). Patients with recurrent HE before transplantation and those with alcoholic liver disease (ALD) are at higher risk. There is a debate in the presence of HE sequelae after LT even if HE symptoms disappear \[[@CR33]--[@CR35]\]. This is because several data suggest that LT reverses the metabolic component of HE, but the structural component may persist \[[@CR36]••\]. The hypotheses behind this assumption are as follows: hyperammonemia from decompensation due to urea cycle defects can lead to long-term neurological sequelae \[[@CR34]\]; correlation between neurological impairment and history of previous episodes of HE \[[@CR37], [@CR38]\]. In contrast, some studies report that HE is totally reversible and that what is thought to be HE sequelae is a manifestation of competitive brain injuries such as from hyperammonemia \[[@CR39]\]. Many LT patients have risk factors for neurocognitive changes such as age, alcoholism, and metabolic syndrome, regardless of previous bouts of HE \[[@CR15]••, [@CR16]\]. An example of a causative factor for post-LT confusion is immunosuppressant drugs because they frequently have toxic effects especially if their blood levels are elevated. Diagnosis of adverse cerebral effects of drugs may be difficult. Infections (bacterial or viral) can result in confusion associated with fever, which requires a diligent workup. In general, altered mental status post-transplant must be approached from a broad clinical view since the etiology is usually multifactorial. The most frequent neurological complications of LT include seizures, stroke, central nervous system (CNS) infections, ICU-acquired weakness, and neurocognitive complications (due to decompensation of previous altered cerebral condition, general anesthesia, surgical procedure, or anticalcineurin toxicity). Factors that can indirectly lead to neurological complications include early graft function impairment, drugs, renal function impairment, sepsis, and altered ammonia clearance \[[@CR40]\]. Some patients who have no history of cerebral impairment or previous evidence of HE can develop neurological impairment after LT. It has been suggested that possible causative factors include adverse effects of general anesthesia, the surgery itself, or postoperative ICU stay \[[@CR41]--[@CR45]\]. There are several causes of ICU admission that are implicated in long-term neurocognitive impairment such as sepsis or acute respiratory distress syndrome \[[@CR41]--[@CR43], [@CR46]\]. Postoperative cognitive dysfunction has been recognized as a common problem that is independently associated with increased mortality outside the scope of LT \[[@CR47]\]. Systemic inflammation has been hypothesized to be a pathophysiological mechanism explaining postoperative cognitive dysfunction or postoperative delirium \[[@CR44]\]. The additional inflammation associated with the LT surgery worsens the pre-existing systemic inflammation in acute liver failure (ALF) and cirrhosis. Additional pre-LT risk factors that have been reported include duration of surgery, infections, and mechanical ventilation \[[@CR48]\]. Evidence suggests that patients with cirrhosis tend to demonstrate long-lasting cognitive impairment after infection \[[@CR49]\]. Other causes for cerebral impairment are the changes in cerebral blood flow and systemic hemodynamics.Fig. 1Factors that affect the cognitive function before and after liver transplant

Long-Term and Short-Term Changes in Cognition {#Sec4}
=============================================

HE is presumed to be largely reversed after successful LT \[[@CR50]\]. Data on long-term cognitive changes post-LT are variable (Table [1](#Tab1){ref-type="table"}). Some studies have shown a continued improvement in cognitive function, while others have reported the contrary \[[@CR10], [@CR62]•\]. These neurocognitive deficits are assessed by extensive psychometric neurocognitive testing and have been confirmed by EEG, different MRI techniques, and positron emission tomography (PET) scanning \[[@CR52], [@CR62]•\]. MRI studies that use standard sequences, magnetic resonance spectroscopy (MRS), diffusion tensor imaging (DTI), and functional MRI are capable of showing changes in cerebral abnormalities before and after LT \[[@CR51]--[@CR53], [@CR55]\]. Only a few studies have investigated the role of multi-modal brain MRI changes over a longer time period and reported conflicting results from longitudinal analyses of these MRI changes \[[@CR32], [@CR52], [@CR65]\]. A study analyzed changes in magnetization transfer ratio (marker for brain edema) and MRS, and reported a progressive improvement in both markers between pre-LT, 1 month post-LT, and 1 year post-LT without continued improvement in cognition at 1 year post-LT \[[@CR62]•\]. Another study showed improved extracellular cerebral edema and cognitive tests, but also possibly advanced white matter demyelination in the temporal lobe, 6 to 12 months after transplant \[[@CR65]\]. It has been reported that there is a significant improvement in cognitive performance and health-related quality of life (HRQOL) at 6 months post-LT, accompanied by a significant improvement in white matter integrity and astrocytic consequences of hyperammonemia on multi-modal MRI \[[@CR63]\]. Despite limited data from DTI, it appears that mean diffusivity (MD) decreases after LT, suggesting reversal of vasogenic edema with the improvement of liver function \[[@CR36]••, [@CR59], [@CR61]\]. It has been reported that MRS peaks can normalize as early as 3 months after LT \[[@CR52]\]. Less is known about the results from functional MRI; however, improvement in cerebral function after LT was suggested \[[@CR61], [@CR66]--[@CR70]\]. On the other hand, there is evidence reporting reduction in brain volume and a decrease in the MRS N-acetylaspartate (NAA)/creatinine (Cr) ratio which suggest the presence of structural brain changes and atrophy \[[@CR32]\].Table 1Studies on cognitive changes after LTReferences (authors, year)Patient populationTime period pre-LTTime period post-LTMethodsFindingsWeissenborn et al. \[[@CR51]\], 199550 cirrhotic patients3 months3 months1T MRI scanner, T1, T2\*Bilateral T1 hypersignals of the globus pallidus before LT; absent 3 months after LT\*T2 hypersignals in the corticospinal tract (18% of the patients)\*No correlation between the T1 signal intensity and liver function, neurological status, or grade of encephalopathyCórdoba et al. \[[@CR52]\], 200124 cirrhotic patients1.5T MRI scanner, magnetization transfer imaging, 1H-MRS\*Bilateral T1 hypersignals of the globus pallidus still present at 1 month after LT but normalized at 1 year\*MTR increase in frontal and parietal lobesRovira et al. \[[@CR53]\], 200224 cirrhotic patients12 months1 month and 1 year1.5T MRI scanner, T2, Fast-FLAIR, magnetization transfer imaging\*White matter T2 hypersignals in the corticospinal tract decrease after LTRovira et al. \[[@CR54]\], 200727 cirrhotic patients6 to 14 months6 to 14 months1.5T MRI scanner, T2, Fast-FLAIR\*White matter (WM) T2 hypersignals decrease after LT\*WM lesions were more common in cirrhosis of viralEtiologyGarcía Martínez et al. \[[@CR55]\], 201022 cirrhotic patients6--12 months and 6--9 years6--12 months and 6--9 years1.5T MRI scanner, T2, Fast-FLAIR\*WM T2 lesions decrease, particularly in patients with previous bouts of HE before LT\*Brain atrophy estimated at 8% decrease compared with before LT in short-term assessment and at 22% decrease in long-term assessmentPegum et al. \[[@CR56]\], 201192 abstinent patients with ALDNS12 monthsPsychometric tests (WAIS-R, WAIS-III, TMT-A and TMT-B, WMS, RCFT)\*Overall improvement in cognitive function occurs after liver transplantation in ALDGarcia-Martinez et al. \[[@CR32]\], 201152 cirrhotic patients2 months6--12 monthsPsychometric tests (RAVLT, TMT-A, SDMT, GPT, COWAT, HVOT, JLO)\*The association of HE with cognitive function and brain volume suggests that having experienced HE before LT impairs the post-LT neurological outcomeGarcia-Martinez et al. \[[@CR32]\], 201124 cirrhotic patientsNS6--12 months1.5T MRI scanner, 1H-MRS\*Reduced brain volume in older patients, alcohol use, prior HE, and increased time from first episode of HE\*Age-related decrease in brain volume was higher in patients with prior HEMattarozzi et al. \[[@CR57]\], 201212 cirrhotic patientsNS7--10 yearsPsychometric tests (VM, COAT, TMT-A, and TMT-B, SCT, digit span, Corsi test, VMT, RWIR, RWDR, brief story, PAL, supraspan learning, RCFRT, FAS, PC, Pcopy, PCopy, RCFT, DSST; Elithorn maze test)\*The improvements obtained in the first 2 years after LT remain stable during the 7 to 10 years thereafter, indicating long-term improvement in cognitive function after LTLi et al. \[[@CR58]\], 201325 cirrhotic patientsNS1 weekPsychometric tests (MMSE, VFT, DSTs, item memory, source memory (SM))\*Incidence of POCD in LT patients was greater than that reported in other surgical patients\*There was increase in the serum biomarkers of dementia in the POCD patientsIshihara at al. \[[@CR59]\], 201312 cirrhotic patientsJust before LT6 monthsPsychometric tests (MMSE, TMT-A and TMT-B, SCT, DSST, digit span, visual reproduction (plus delayed recall))\*End-stage cirrhotic patients without clinical evidence of HE showed increased MD and decreased FA values in both frontal and temporal lobes. These parameters improved after LT, in line with cognitive functionTryc et al. \[[@CR60]•\], 201481 cirrhotic patients6 months6 and 12 monthsPsychometric tests (PHES, ICT, CFF, RBANS)\*1 year after LT, cognitive dysfunctions in LT patients are not residual symptoms but instead are new-onset cognitive disturbances\*Cognitive deficits are linked to a decline in health-related quality of lifeLin et al. \[[@CR61]\], 201428 cirrhotic patients 30 controlsNS6--12 monthsPsychometric tests (WAIS-III, CASI, Wisconsin Card Sorting Test)\*Improvement of the extracellular cerebral edema and of the demyelination of WM in MHE patients after LT\*DTI may be useful for investigating the pathogenesis of MHECampagna et al. \[[@CR62]•\], 201465 cirrhotic patientsNS3, 6, 9, and 12 monthsPsychometric tests (TMT-A and TMT-B, digit span, VFT, DSST, memory with interference task at 10 s and at 30 s, immediate and delayed story recall memory)\*Both neuropsychological and EEG performances had significantly improved 1 year after LT\*Patients with a history of OHE showed greater improvements after LT than patients with a negative history, but their global cognitive function remained slightly worse; in contrast, EEGs normalized in both groupsAhluwalia et al. \[[@CR63]\], 201643 cirrhotic patients6 months6 months1.5T MRI scanner, T1, T2\*No abnormalities on standard weighted sequencesPflugrad et al. \[[@CR64]\], 201785 patients who underwent LT12 months12 months3T MRI scanner, T1, T2\*Higher WM hypersignals in patients under CNI but no brain atrophy\*Patients had more brain atrophy than controls\*Patients under CNI had lower neuropsychological performance*RBANS*, repeatable battery for the assessment of neuropsychological status; *WAIS-III*, Wechsler Adult Intelligence Scale, Third Edition; *CASI*, Cognitive Ability Screening Instrument; *VFT*, verbal fluency test; *TMT-A*, Trail Making Test, A; *TMT-B*, Trail Making Test, B; *DSTs*, Digit Span Forward and Digit Span Backward tests of the Wechsler Adult Intelligence Scale; *DSST*, digit symbol substitution test; *WAIS-R*, Wechsler Adult Intelligence Scale, Revised; *NS*, not stated; *ND*, not done; *RAVLT*, Rey auditory verbal learning test; *COWAT*, Controlled Oral Word Association Test; *JLO*, Judgment of Line Orientation; *SDMT*, Symbol digit modalities test; RCFT, Rey--Osterrieth Complex Figure Recall Trial; *GPT*, Grooved Pegboard test; *HVOT*, Hooper Visual Organization Test; *WMS*, Wechler Memory Scale; *SCT*, Stroop color test; *RBMT*, Rivermead Behavioral Memory Test; *SRT*, simple reaction time; *CRT*, choice reaction time; *NART*, National Adult Reading Test; *COAT*, crossout a test; *VM*, visual matrices; *VMT*, Immediate Visual Memory Test; *RWIR*, Rey Auditory Verbal Learning Test immediate; *RWDR*, Rey Auditory Verbal Learning Test 15-min delay recall; *PAL*, paired associate learning; *PC*, Phrase Construction; *FAS*, word fluency; *PCopy*, Painting Copy; *PCopyF*, Painting Copy with Facilities; *RCFC*, Rey--Osterrieth Complex Figure Copy; *WM*, white matter; *MHE*, minimal hepatic encephalopathy; *OHE*, overt hepatic encephalopathy; *POCD*, postoperative cognitive dysfunction; *ALD*, alcoholic liver disease; *CNI*, calcineurin inhibitor

What Are the Expectations? {#Sec5}
==========================

There are practice guidelines that have been published for the management of transplant candidates \[[@CR71], [@CR72]\]. HE alone is not considered an indication for LT unless associated with poor liver function. However, exceptions exist where cases may be candidates for LT even though liver status is good if there is severe compromise to the patient's quality of life and lack of improvement despite maximal medical therapy. Due to the fact that neurocognitive impairment may occur or persist even after LT, it is highly recommended to evaluate for presence of shunts and consider embolization before or during transplantation \[[@CR73]\]. Furthermore, during transplant evaluation, severe hyponatremia should be corrected slowly. Based on evidence from published date, LT is expected to improve HE but not neurodegenerative disorders. Therefore, it is important to distinguish HE from other causes of neurocognitive impairment such as Alzheimer's disease and small-vessel cerebrovascular disease. Brain MRI and MRS should be performed, and the patient should be evaluated by a neuropsychology specialist and an expert in neurodegenerative diseases \[[@CR74]\]. Patients and caregivers, especially in patients with prior HE and cognitive dysfunction, need to be counseled prior to listing about the expectations for recovery of brain function in the short-term and long-term course post-LT extensively. There are certain subgroups in which complete recovery may take decades, and in some subgroups, it may remain impaired. In some patients, there may even be new-onset cognitive dysfunction after LT. However, in most cases, these changes are manageable and do not interfere with daily function and independence post-LT. Regardless, pre-transplant counseling should involve a discussion regarding cognitive and functional expectations of the family and patients after liver transplant.
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